Efficacité et innocuité du tacrolimus pour la myasthénie grave: revue systématique et méta-analyse.

Verrouillé
Avatar du membre

Auteur du sujet
Pboulanger Prés.
Administrateur
Administrateur
Messages : 10762
Enregistré le : 02 févr. 2010 18:41
14
Localisation  : La Chapelle en Serval F-60520
Genre :
Zodiaque :
Âge : 67
    Windows 10 Firefox

Efficacité et innocuité du tacrolimus pour la myasthénie grave: revue systématique et méta-analyse.

Message par Pboulanger Prés. »

:hi:

:arrow: Lu sur :https://www.ncbi.nlm.nih.gov/pubmed/28921038

[ligne][/ligne]

Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum

Image

[ligne][/ligne]

Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L1, Zhang S2, Xi J1, Li W3, Zhou L1, Lu J1, Lu J1, Zhang T4, Zhao C5,6.
J Neurol. 2017 Sep 18. doi: 10.1007/s00415-017-8616-7.

Abstract

To evaluate the efficacy and safety of tacrolimus in patients with myasthenia gravis (MG), a systematic review and meta-analysis was performed. We searched PubMed and Embase for randomized controlled trials and clinical controlled trials in English language.

Demographic and clinical characteristics of the MG patients were extracted. Differences in the current glucocorticoids (GC) dose in each included study were the primary outcome measure.

The adverse events reported in each included study were used as safety evaluation. There were 5 trials included involving 683 patients. In this systematic review, we identified treatment with tacrolimus did not exhibit a statistically significant difference in the GC dose reduction at 6 months and 12 months compared with placebo.

The standard mean differences in the GC dose reduction were -1.95 [(-4.20 to 0.30); p = 0.09] at 6 months and -1.72 [(-4.21 to 0.77); p = 0.18] at 12 months. But GC dose reduction from baseline in the tacrolimus group exceeded that in the controlled group. The weighted mean differences were -1.34 [(-2.46 to 0.23); p = 0.02] in the quantitative myasthenia gravis score and -1.10 [(-1.84 to -0.36); p = 0.004] in the myasthenia gravis activities of daily living score at 6 months.

Adverse events were recorded in 80 of 347 patients (23%) treated with tacrolimus and most of them were mild. This meta-analysis proves that tacrolimus therapy is beneficial to improve clinical symptoms in MG patients.

Tacrolimus may be a worthy therapy to relieve MG symptoms.
Message d' un membre de l'équipe technique
Nous utilisons un service automatique de traduction fourni par YANDEX.
Soyez vigilant sur le risque de contre-sens inhérent à ce genre d'outils.

Lien Google traduction https://translate.google.fr/translate?s ... t=&act=url
Amicalement,
Image
Verrouillé

Retourner vers « 2017 »